GKGülay Koçak

Gülay Koçak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gülay Koçak has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Polycythemia due to SGLT-2 inhibitors: who is at risk?

    by Hediye Büşra Ergün Arıkan, Gülay Koçak, Funda Yalçın, Kadir Bilgi, Mahmut Altındal

    Introduction Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are oral antidiabetic agents that have been increasingly used in recent years. One of their lesser-known adverse effects is polycythemia (erythrocytosis), for which data remain limited. In this study, we aimed to investigate the incidence of erythrocytosis associated with SGLT-2 inhibitor use and the risk factors influencing these changes. Methods All patients who initiated SGLT-2 inhibitor therapy in our clinic between January 2020 and January 2021 were retrospectively evaluated. Hb and Hct levels were monitored for a median of 16 months following treatment initiation. Results Polycythemia developed in 15.1% (n = 58) of the 385 patients included in the study. Male sex and smoking were identified as significant risk factors for erythrocytosis, whereas insulin use and iron deficiency were found to be protective factors. The mean increase in hemoglobin levels among all patients was 0.97 ± 0.94 g/dL. A negative correlation was observed between baseline Hb levels and the degree of Hb increase associated with SGLT-2 inhibitor use. Patients who were excluded from the study due to baseline polycythemia (n = 18) were evaluated separately, and no significant change in their Hb levels was detected during follow-up. Conclusions SGLT-2 inhibitors significantly increase Hb and Hct levels in all patients without polycythemia. In anemic individuals, SGLT-2 inhibitors appear to induce greater increases in Hb and Hct, suggesting a potential additional hematologic benefit in this subgroup. Moreover, SGLT-2 inhibitors have been shown to be safe in patients with pre-existing polycythemia.

  • Open Access

    Awareness, perceptions, and clinical practice approaches of nephrologists toward the periodontal disease–chronic kidney disease association

    by Seval Ceylan Şen, Özlem Saraç Atagün, Gülbahar Ustaoğlu, Tuğçe Paksoy, Meral Gülay Kadıoğlu Koçak

    Aims: Periodontitis is a chronic inflammatory condition implicated in the pathogenesis of systemic diseases, including chronic kidney disease (CKD), primarily through low-grade systemic inflammatory pathways. Given the potential impact of periodontal health on CKD progression, this study aims to assess nephrologists’ awareness, attitudes, and clinical practices regarding the association between periodontal disease and CKD. Methods: This cross-sectional study used a structured, literature-based questionnaire distributed via Google Forms to nephrologists. Participation was voluntary, and informed consent was obtained online. The survey included demographic questions and items assessing awareness, attitudes, and clinical practice approaches regarding the interrelationship between periodontal disease and CKD. A total of 144 nephrologists completed the survey. Multivariable binary logistic regression was employed to identify independent predictors of participants' oral health education status.Results: Of the 144 nephrologists surveyed, most were aged 45–54 years, had 11–20 years of experience, and worked in university hospitals following over 100 CKD patients monthly. While general awareness of the oral–renal connection was moderate to high, many participants did not routinely take oral health histories or recognize uremic manifestations. Nonetheless, the majority reported referring patients with oral complaints to dentists. Prior training in oral health and recent dental visits were associated with higher awareness and more positive attitudes. Regression analysis identified age as a significant predictor of prior training, with nephrologists aged 35–44 and 55+ being 7.4 times more likely to have received oral health education (p=0.036).Conclusion: Since age was identified as a significant predictor of prior training, with younger nephrologists being less likely to have received oral health education, targeted interdisciplinary programs focusing on early-career specialists are essential to bridge this knowledge gap. Furthermore, the inverse relationship between educational opinions and prior training emphasizes a strong perceived need for such interventions among untrained professionals.

  • Open Access

    Association Between SGLT2 Inhibitor Use and Post-Contrast Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Multicenter Cohort Study

    by Alper Azak, Munevver Gul Avsar, Gülay Koçak, Alper Koyuncuoğlu, Kadriye Kılıçkesmez, Özge Kama Başcı, Eyup Avcı

    Introduction: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of coronary artery disease and frequently undergo coronary angiography or percutaneous coronary intervention. Although risk factors for post-contrast acute kidney injury (PC-AKI) are well defined, effective preventive strategies remain limited. Methods: This multicenter observational cohort study included 975 patients aged 18–75 years who underwent coronary angiography and/or percutaneous coronary intervention with iodinated contrast between June 2023 and June 2024. All patients received standardized intravenous hydration. Participants were grouped according to chronic sodium–glucose co-transporter-2 (SGLT2) inhibitor use (≥3 months). PC-AKI was defined as a ≥25% or ≥0.5 mg/dL increase in serum creatinine within 48–72 hours after contrast exposure. Results: The mean age was 59.2 ± 11.7 years, and 70.8% were male; 16.9% were using SGLT2 inhibitors. PC-AKI occurred in 7.3% of patients, and 0.7% required renal replacement therapy. In univariate analysis, advanced age, diabetes, hypertension, heart failure, diuretic use, and elevated urea, creatinine, potassium, and uric acid levels were associated with PC-AKI. Higher eGFR, albumin, sodium levels, and SGLT2 inhibitor use were inversely associated. In multivariate analysis, age ≥65.5 years (OR 4.53), diabetes (OR 2.49), and uric acid >6.75 mg/dL (OR 2.34) remained independent risk factors, while eGFR >81.5 mL/min/1.73 m 2 (OR 0.38), sodium >137.5 mmol/L (OR 0.36), and SGLT2 inhibitor use (OR 0.09) were independently protective. Conclusion: Beyond established cardioprotective and renoprotective effects, SGLT2 inhibitors may reduce the risk of PC-AKI in patients with T2DM, potentially through decreased renal oxygen consumption and attenuation of contrast-induced hypoxic injury.

  • Use of Procalcitonin for Detection of Bacterial Infection in Patients With Chronic Kidney Disease: A Retrospective Cohort Study

    by Onder Sabahat, Aylia Yesilova, Namigar Turgut, Gulay Kocak

    Aim: Procalcitonin (PCT) interpretation in chronic kidney disease (CKD) patients is challenging, as levels may rise even without infections. This study aimed to evaluate PCT dynamics during bacterial infections across CKD stages and assess its diagnostic utility. Material and Methods: In this retrospective, single‐center study, 505 hospitalized patients (293 with CKD and 212 controls) with confirmed bacterial infections were included. Patients were classified according to KDIGO CKD stages. PCT levels were measured at 24, 48, 72, 96 h, and at discharge. Results: PCT levels were significantly higher in CKD patients compared to those without CKD at all time points. Levels tended to increase or remain elevated with advancing CKD stage, except in stage 5. A significant decline in PCT was observed at the 96th hour, with a delayed decrease in advanced CKD. Conclusion: PCT is a valuable biomarker for bacterial infections in CKD; however, stage‐specific thresholds may be necessary to avoid misdiagnosis and improve clinical utility.


  • Evaluation of contrast induced nephropathy related risk factors and long‐term results

    by Alper Koyuncuoğlu, Münevver Gül Avşar, Ahmet Tarhan, Muhammed Emin Oktay, Selin Sağlam, Gülay Koçak, Kadriye Kılıçkesmez

    Introduction: We aimed to evaluate the frequency of contrast induced nephropathy (CIN), its relationship with accepted risk factors and long‐term renal outcomes in patients who underwent coronary angiography (CAG).Methods: All patients who underwent CAG between April 2020 and April 2021 were retrospectively evaluated. CIN was defined as characteristic increase in serum creatinine after CAG.Results: CIN developed in 50 (5.4%) of 934 patients. The CIN rate was found to be statistically significantly higher in patients with diabetes, hypertension, heart failure and those using diuretics. Pre‐procedural hemoglobin, albumin and GFR were found to be independent risk factors for CIN. After discharge, the urea and creatinine values of the patients who developed CIN were significantly higher than those who did not.Conclusion: We concluded that in order to reduce the development of CIN, hemoglobin and albumin levels should be evaluated with renal functions before the procedure and they should be kept within normal limits.


  • Open Access

    Comparison of clinical characteristics and outcomes of acute kidney injury in the elderly and younger hospitalized patients

    by A. Yesilova, I.D. Toprak, Y.E. Uzun, M. Cengiz, B.O. Turkmen, H. Yavuzer, G. Kocak

    Data regarding the epidemiology, causes, and outcomes of acute kidney injury (AKI) are limited, especially in the elderly population. We aimed to investigate the clinical characteristics and early outcomes of AKI and to compare them between elderly and young patients hospitalized in an internal medicine clinic. Methods. This single-center retrospective study included patients with AKI who were hospitalized in a tertiary hospital. AKI was identified according to the Kidney Disease Improving Global Outcomes criteria. Sociodemographic, clinical, and laboratory data were recorded. Renal recovery, need for dialysis, and in-hospital mortality were compared between the elderly (>60 years) and younger (≤60 years) patients. Results. A total of 454 patients (327 elderly and 127 younger) were included in the study. The frequency of AKI in hospitalized patients was 12%. The most common cause of AKI was prerenal (61%). Prerenal AKI due to absolute intravascular volume reduction was the most important cause in both groups. Compared with the elderly patients, younger patients exhibited an increased rate of renal AKI (23% vs. 39%, p=0.001) and an increased need for dialysis during hospitalization (21% vs. 31.5% p=0.027). The incidence of vasculitis and glomerulonephritis was higher in younger patients with renal AKI than in the elderly patients (12% vs. 1.3% for vasculitis and 24% vs. 4% for glomerulonephritis p=0.001). Twenty-four percent of patients required dialysis during hospital stay and 10% required dialysis at discharge. The overall in-hospital mortality was 6,4%. Considering the AKI pathophysiology, the highest mortality rate was observed in AKI patients with renal origin (3.5%). There were no significant differences between elderly and younger patients based on renal recovery (complete recovery, 41% vs. 50%; progression 59% vs. 50%, p=0,073), hospital mortality (5.5% vs. 6.7%, p=0.634), and the need for dialysis at discharge (14% vs. 8.8%, p=0.082). Conclusions. In our study, we concluded that there was no significant difference between elderly and younger hospitalized patients according to the early outcomes of AKI. However, the younger patients had a higher rate of renal AKI with a more severe course.

  • Open Access

    The evaluation of urinary calprotectin levels for prediction of acute cisplatin-induced nephrotoxicity

    by Gülay Koçak, Gamze Bilik, Aylia Yeşilova, Firat Oyman, Murat Can, Şener Cihan

    Calprotectin is a protein molecule that is released from inflammatory cells. Measurement of calprotectin in various body fluids has recently gained significant importance for differentiating inflammatory and noninflammatory events. The subject has aroused interest in the field of nephrology and some renal pathologies in which urinary calprotectin levels have been studied. In this study, the measurement of urinary calprotectin level and its use for determining acute cisplatin nephrotoxicity in a group of patients with non-small cell lung cancer who received cisplatin-based oncological treatments have been investigated. The study included 41 patients who received cisplatin-based treatments for non-small cell lung cancer between January 2019 and January 2020. The patients were excluded from this study who were with estimated glomerular filtration rate (eGFR) 1.5 mg/dL, a history of urinary tract infection, and nephrotoxic drug use in the past month. Baseline and 48-hour sCr values and baseline, 6-hour, 12-hour, 24-hour, and 48-hour urinary calprotectin levels of all patients were measured. Four of the 41 patients who received cisplatin treatment were excluded because their 48-hour sCr values could not be accessed. The control group included 29 patients. While there was no difference between the cisplatin group and the control group in terms of baseline sCr and eGFR values, the cisplatin group had significantly higher urinary calprotectin values. Of the 37 patients treated with cisplatin, 7 (18.9%) developed cisplatin-induced nephrotoxicity. The comparison of groups with (group 1) and without cisplatin nephrotoxicity (group 2) showed comparable mean age and male sex ratio. Baseline sCr and eGFR values were similar in both groups. The cisplatin-induced nephrotoxicity group had significantly higher 48-hour sCr and significantly lower 48-hour eGFR values. Baseline, 12-hour, 24-hour, and 48-hour urinary calprotectin levels were similar in groups with and without cisplatin nephrotoxicity. Recent studies have demonstrated that urinary calprotectin level measurement can be used to distinguish intrinsic acute kidney disease from prerenal kidney disease. However, the comparison of groups with and without cisplatin nephrotoxicity in our study showed no difference in urinary calprotectin levels. However, there is a need for large-scale studies using combined urinary biomarkers.


  • Open Access

    Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis

    by Bülent Huddam, Alper Azak, Volkan Karakus, Alper Alp, Dilek Gibyeli Genek, Meral Gülay Kadioglu Kocak, Yelda Dere, Dilek Ersil Soysal, Murat Duranay

    Flow-mediated vasodilation (FMD) has been demonstrated to be a useful, non-invasive tool for the detection of endothelial dysfunction in atherosclerotic cardiovascular disease, the leading cause of mortality in end-stage kidney disease. The Fas/Fas ligand system of apoptosis resulting from activation of the caspase cascade- contributes to the pathophysiology of atherosclerosis. This ‘apoptotic’ system plays a central role in immune homeostasis. Vascular endothelial cells and inflammatory cells are the main resources of the Fas ligand. In this study, we aimed to investigate the role of soluble Fas ligand (sFasL) as a marker of FMD in peritoneal dialysis (PD) patients. Methods. A total of 43 patients undergoing maintenance PD and 40 healthy donors were enrolled in this cross-sectional observational study. Demographics, anthropometric measurements and clinical examinations were obtained. Endothelial function was evaluated by FMD of the brachial artery with high-resolution ultrasonography. Serum sFasL concentrations were measured with an enzyme-linked immunosorbent assay kit. Results. The enrolled partisipants were devited on 2 groups: PD patients who had been treated at least 12 weeks (group 1; mean age 41±14 years, M/F: 22/21) and gender matched 40 healthy controls (group 2; mean age 50±12 years, M/F: 19/20). The forearm FMD and serum sFasL levels were significantly lower in PD patients (3.95±2.01 vs 8.83 ± 6.17; p<0.001 and 54 ± 24 vs 73 ± 30; p=0.001). Forearm FMD was correlated with sFasL (r=0.289; p=0.008), age, BMI and uric acid (r= 0,32; p=0.003, respectively), hemoglobin (r= 0,293; p=0.007), calcium (r= 0,26; p=0.016), phosphate (r=- 0,250; p=0.023), magnesium (r= 0,255; p=0.020), 24 h SBP (r=- 0,257; p=0.019), creatinine and iPTH (r=- 0.50 and r=- 0,45; p<0.001, respectively). After adjustment for age, the stepwise multivariate analysis showed sFasL was independently associated to FMD (β: 0.180; p=0.03, CI: 0.078-0.314). vs 73 ± 30; p=0.001). Conclusions. sFasL may be used as a simple screening marker for endothelial dysfunction in PD patients.

  • Evaluation of acute and chronic nephrotoxicity in patients received cisplatin-based chemotherapy: has anything changed over time?

    by Şule Çelik Kamacı, Gülay Koçak, Aylia Yeşilova, Şener Cihan

    Purpose The aim of this study was to determine the frequency and the risk factors of acute and chronic nephrotoxicity in patients who received cisplatin due to malignancy. Materials and methods Medical records of all patients who received cisplatin-based chemotherapy regimen between January 2013 and July 2019 were retrospectively evaluated. The data of 203 patients who met the study criteria were examined. The patients were evaluated for acute nephrotoxicity at 48 h and late nephrotoxicity at 3rd month after first course of cisplatin. Early and late nephrotoxicity were defined by NCI CTCAE Version 4.0 criteria. Results The mean age of the study patients was 56.44 ± 12.69 years, 78.8% were males and 21.2% were females. It is revealed that the incidence of cisplatin-induced acute nephrotoxicity was 9.2% and chronic nephrotoxicity was 37.9%. While the development of acute nephrotoxicity was associated with female gender, history of diabetes mellitus, history of ischemic heart disease and use of antiplatelet drug, the development of chronic nephrotoxicity was associated with older age, female gender and using of diuretics. High serum creatinine, urea and low eGFR value before treatment were found to be associated with both early and late nephrotoxicity (p < 0.05). There was no statistically significant relationship between acute or chronic nephrotoxicity and cumulative dose of cisplatin, hydration or intravenous magnesium supplementation. Conclusion High initial serum creatinine value and low initial eGFR are the most important determinants of both early and late nephrotoxicity.


  • Open Access

    MCP-1 and soluble TWEAK levels are independently associated with coronary artery disease severity in patients with chronic kidney disease

    by Mehmet Fatih Akdoğan, Alper Azak, Nazım Denizli, Bülent Huddam, Gülay Koçak, Murat Gücün, Mustafa Adem Tatlısu, Recep Demirci, Bilal Yılmaz, Mehmet Dikeç, et al.

    Purpose: Patients diagnosed with chronic kidney disease (CKD) have a greater rate of cardiovascular mortality when compared with the general population. The soluble form of TNF-like weak inducer of apoptosis (TWEAK) and monocyte chemoattractan protein 1 (MCP-1) play important roles in cellular proliferation, migration and apoptosis. The current study aimed to analyze whether soluble TWEAK (sTWEAK) and MCP-1 levels are associated with the severity of coronary arterial disease (CAD) in CKD patients. Methods: Ninety-seven patients diagnosed with CKD stages 2–3 according to their estimated glomerular filtration rate and the presence of kidney injury were included in the study. Plasma sTWEAK and MCP-1 concentrations were determined using commercially available ELISA kits. Coronary angiographies were performed through femoral artery access using the Judkins technique. Results: Correlation analysis of sTWEAK and Gensini scores showed significant association (p < 0.01, r2 = 0.287). Also significant correlation has been found in MCP-1 levels and Gensini scores (p < 0.01, r2 = 0.414). When patients were divided into two groups with a limit of 17 according to their Gensini score, sTWEAK levels indicated a statistically significant difference (p < 0.01). Conclusions: Our findings support a relationship between sTWEAK and MCP-1 levels and CAD in CKD stages 2–3 patients.